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Abstract
Introduction—US obstetrician/gynecologists (ob-gyns) play a critical role as vaccinators of 
pregnant women. However, little is known about their current immunization practices. Thus, study 
objectives were to determine: 1) practices related to assessment of vaccination status and vaccine 
delivery for pregnant patients; 2) barriers to stocking and administering vaccines; and 3) factors 
associated with administering both influenza and tetanus, diphtheria, and acellular pertussis (Tdap) 
vaccines.
Methods—An e-mail and mail survey among a national sample of ob-gyns conducted July-
October 2015 (analysis August 2016-August 2017).
Results—The response rate was 73.2% (353/482). Among ob-gyn’s caring for pregnant women 
(n=324), vaccination status was most commonly assessed for influenza (97%), Tdap (92%), and 
measles, mumps, and rubella (MMR) vaccines (88%). Vaccines most commonly administered 
included influenza (85%) and Tdap (76%). Few respondents reported administering other vaccines 
to pregnant patients. More physicians reported using standing orders for influenza (66%) than 
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Tdap (39%). Other evidence-based strategies for increasing vaccine uptake were less frequently 
used (electronic decision support, 42%; immunization information system (IIS) to record (13%) or 
assess vaccination status (11%); reminder/recall, 7%). Barriers most commonly reported were 
provider financial barriers; provider attitudinal barriers were rare. Providers who administered 
both influenza and Tdap vaccines were more likely to be female, perceive fewer financial and 
practice barriers and less likely to be in private practice and perceive more patient barriers.
Conclusion—While most ob-gyns administer some vaccines to pregnant women, the focus 
remains on influenza and Tdap. Financial barriers and infrequent use of evidence-based strategies 
for increasing vaccination uptake may be hindering delivery of a broader complement of adult 
vaccines in ob-gyn offices.
INTRODUCTION
Pregnant women are at increased risk for severe disease from influenza,1–5 and their 
newborns are at increased risk of morbidity and mortality from both influenza6–8 and 
pertussis.9,10 Influenza and pertussis vaccination are therefore now routinely recommended 
for all pregnant women,11,12 with influenza vaccination recommendations in place since 
2004. The initial recommendation for tetanus, diphtheria, and acellular pertussis (Tdap) 
vaccination in 2011 was for pregnant women with no history of prior Tdap, but, in 2012, 
was extended to all pregnant women during each pregnancy. Both vaccines are safe and 
effective.13–27
However, despite the benefits of these vaccines for pregnant women and their newborns, 
uptake remains low: according to the most recent national data, only 50% of pregnant 
women received influenza vaccine before or during pregnancy and only 41% of pregnant 
women received Tdap during pregnancy.28–31 While some of the barriers to increased uptake 
are related to patient concerns about vaccine safety in pregnancy,32 there are also provider 
barriers. In a recent national survey, a substantial proportion of pregnant women reported 
receiving neither a recommendation nor an offer for an influenza vaccine from a provider. 
These women were far less likely to receive an influenza vaccine (20%) than those who 
received both a recommendation and an offer (65%).28
There are other vaccines recommended for pregnant women in certain circumstances, such 
as hepatitis A and B vaccines, pneumococcal vaccines, and meningococcal vaccines.33 
Pregnancy represents an opportunity for adult vaccination given the high number of contacts 
with the obstetrician/gynecologist’s (ob-gyn) office during a routine pregnancy. Little is 
known about ob-gyn current practices regarding use of all indicated vaccines in pregnancy, 
as there has been no recent national assessment. This study sought to address this gap in the 
literature by assessing among a national sample of ob-gyns: 1) current practices related to 
assessment of vaccination status and vaccine delivery for pregnant patients; 2) barriers to 
stocking and administering vaccines in ob-gyn practices; and 3) factors associated with 
administering both influenza and Tdap vaccines to pregnant patients.
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METHODS
Between 7/2015 and 10/2015, an Internet and mail survey was administered to a national 
network of ob-gyns representative of American College of Obstetricians and Gynecologists 
(ACOG) membership. The IRB at the University of Colorado Denver deemed this study 
exempt research not requiring informed consent.
Study Population
The Vaccine Policy Collaborative Initiative conducted this study.34 The Initiative is a 
program designed collaboratively with CDC to perform rapid turnaround surveys assessing 
physician practices and attitudes about vaccine-related issues. A national network of ob-gyns 
was developed for this program by recruiting from ACOG. Quota sampling was conducted 
to ensure that network physicians were similar to ACOG membership with respect to region, 
urban versus rural location, and practice setting. In prior work, survey responses from 
network physicians compared to those of physicians randomly sampled from American 
Medical Association physician databases were similar in regard to demographic 
characteristics, practice attributes, and attitudes about a range of vaccination issues.34 
Physicians who reported that they only cared for non-pregnant patients were excluded from 
this study.
Survey Design
The survey was jointly developed with CDC with input from experts in vaccination and 
obstetrics and gynecology. Survey questions followed formats previously used in published 
surveys.35–37 The survey was pre-tested with a panel of 6 ob-gyns and then piloted among 
38 ob-gyns from different regions of the country. Questions regarding assessing and 
administering vaccines and use of evidence-based practices were asked using a series of 
yes/no questions. Questions regarding frequency of a given practice were assessed using a 4-
point Likert scale (never/rarely, sometimes, often, always). Barriers questions also used a 4-
point Likert scale from ‘not a barrier’ to ‘major barrier.’ Other responses to information 
questions were either yes/no, answers that were not mutually exclusive, or selections from a 
list of possible options.
Survey Administration
Physicians were surveyed via Internet or mail according to their preference. A Web-based 
program (Verint®, Melville, New York, www.verint.com) was used to administer Internet 
surveys, and we sent mail surveys by U.S. Postal Service. The Internet group was sent an 
initial e-mail with up to 8 e-mail reminders, and the mail group was sent an initial mailing 
and up to 2 reminders. Internet survey non-respondents were sent a cross-over mail-based 
survey in case of problems with e-mail correspondence. The mail protocol was patterned on 
Dillman’s tailored design method.38
Statistical Analysis
Internet and mail surveys were pooled for analyses because other studies have found that 
physician attitudes are similar with either method.39 Respondents were compared with non-
respondents on all available characteristics using Wilcoxon and chi-square analyses.
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Physicians who responded ‘yes’ to the query “Do you give the vaccine in your practice?” for 
both influenza and Tdap vaccines were compared to those who responded ‘no’ for either or 
both vaccines. Independent variables included sex, age, practice setting, practice location, 
practice region, and perceived barriers. Perceived barriers were evaluated and grouped using 
a Principal Component Analysis with varimax rotation. Factors were retained if their 
eigenvalue was ≥1. A cut-off of p<0.25 was used for inclusion of independent variables in 
the model. The multivariable model used a backwards elimination procedure in which the 
least significant predictor in the model was eliminated sequentially. At each step, estimates 
were checked to make sure other variables were not affected by dropping the least 
significant variable. This resulted in retention of only those factors that were significant at 
p<0.05 in the final model. Analyses were performed using SAS software, version 9.4 (SAS 
Institute, Cary, North Carolina) August 2016 to August 2017.
RESULTS
The response rate was 73.2% (353/482). Respondents were more likely than non-
respondents to be female, work in a hospital-associated clinic, and have a higher median and 
mean number of providers in their office (Table 1). Overall, 90% reported stocking and 
administering at least one vaccine.
Assessment of Vaccination Status
Ob-gyn physicians were the provider most frequently reported as primarily responsible for 
assessing vaccination status (72%), followed by medical assistants (MA)/licensed 
professional nurses (LPN) (12%), registered nurses (9%), and advanced care providers 
(nurse midwife, nurse practitioner, physician assistant) (6%). Two percent reported no 
routine assessment. Respondents reported multiple methods for assessing vaccination status, 
including checking their own medical records (87%), ob-gyn (85%) and staff (66%) asking 
patients verbally, physician reviewing outside records (61%), asking in a standard 
questionnaire (60%), staff reviewing outside records (32%), and using an immunization 
information system (IIS) (11%). Respondents reported routinely assessing vaccination status 
(other than influenza) most often at initial visits (93%), followed by third trimester (64%), 
first trimester (45%), and second trimester (40%), with 16% reporting they routinely assess 
vaccination status at every visit.
Respondents most commonly reported assessing vaccination status of pregnant women for 
influenza (97%) and Tdap (92%) vaccines (Figure 1). Other vaccines frequently assessed 
during pregnancy included MMR (88%), hepatitis B (77%), and varicella (50%). Ninety-
eight percent of physicians reported assessing serology for rubella and 44% for varicella.
Few respondents reported recording information regarding vaccines received either in the 
office (13%) or outside the office (10%) in an IIS. For vaccines received outside the office, 
the most common method of recording information was in a progress note in an electronic 
medical or electronic health record (EMR/EHR) (69%), followed by a summary sheet in the 
EMR/EHR (61%), a progress note in a paper-based record (19%), and a summary sheet in a 
paper-based record (11%). Ten percent of respondents reported not recording this 
information anywhere.
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Vaccine Administration
Vaccines most commonly administered in the office to pregnant patients included influenza 
(85%) and Tdap (76%) (Figure 1). Vaccines less commonly administered, in descending 
order, included hepatitis B (22%), tetanus and diphtheria (Td) (17%), hepatitis A (10%), 
pneumococcal polysaccharide (10%), pneumococcal conjugate (9%), and meningococcal 
conjugate (7%) vaccines. In cases where a patient was identified as eligible for a vaccine that 
the practice did not stock, the majority of physicians always or often (56%) referred them to 
their primary care provider to receive the vaccine, with fewer referring to a public health 
department (32%) or pharmacy (25%).
Use of Evidence-based Strategies and Vaccination-Related Resources
Most respondents (66%) reported using standing orders for influenza vaccine although only 
39% reported doing so for Tdap. The only other strategy commonly used was electronic 
clinical decision support systems for determining vaccination need (42%) with fewer 
reporting use of paper-based clinical decision support (16%) or reminder/recall (7%). The 
most commonly used resources were primarily CDC materials such as Tdap materials on 
maternal immunization, printed immunization schedules, and the CDC immunization 
website, although relatively high proportions of physicians reported rarely or never using 
any of the materials. Few physicians frequently used ACOG-developed materials. CDC and 
ACOG scheduling ‘apps’ were the least used resources.
Barriers to Stocking and Administering Vaccines
The most commonly cited barriers to stocking and administering vaccines were financial 
(Figure 2). Fifty-three percent of respondents reported lack of adequate reimbursement for 
vaccine purchase and 45% reported lack of adequate reimbursement for vaccine 
administration as major or moderate barriers. There were also logistical barriers such as 
other preventive services taking precedence (47% major or moderate barrier) and the burden 
of ordering and tracking (45% major or moderate barrier) or storing (41% major or moderate 
barrier) vaccines. Patient attitudinal barriers were also commonly reported, with 52% 
reporting patients refusing vaccines because of safety concerns as a major or moderate 
barrier and 40% reporting patients refusing because they don’t believe they are at risk for a 
vaccine-preventable disease. In contrast, attitudinal barriers regarding vaccines among ob-
gyns themselves were quite rare, with few or no respondents reporting as major or moderate 
barriers their concerns about vaccine effectiveness or safety, or personal concerns that their 
patients were not at risk of serious disease from vaccine-preventable illness.
Factors Associated with Giving Both Influenza and Tdap Vaccines
In bivariate analysis, female gender, decreasing age, non-private practice setting, not being 
in the South, lower scores on financial and practice barriers, and higher scores on patient 
barriers were associated with giving both Tdap and influenza vaccines (Table 2). In 
multivariable analysis, however, the age effect and South region fell out of the model, so that 
after adjustment, factors associated with giving both influenza and Tdap vaccines included 
female gender (prevalence ratio [PR], 0.78 male referent to female, 95% CI, 0.66–0.93), not 
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being in private practice (1.23 [1.08–1.39]), lower perceived financial (0.86 [0.77–0.96]) and 
practice (0.87 [0.78–0.97]) barriers, and higher perceived patient barriers (1.16 [1.07–1.26]).
DISCUSSION
In this national survey of US ob-gyns, almost all report assessing vaccination status for 
influenza and Tdap vaccine among their pregnant patients, and most report stocking and 
administering these vaccines in their practice as well. This study represents the first data 
regarding the use of Tdap vaccine by ob-gyns since the changes in recommendations that 
occurred in 2011 and 2012. Three-quarters of ob-gyns now report administering the vaccine. 
However, relatively fewer ob-gyns assess vaccination status for other vaccines potentially 
recommended during a pregnancy, and even fewer administer other vaccines that pregnant 
women may need in certain circumstances, such as hepatitis A or B vaccines. Also, few 
obstetricians participate in an IIS.
This study offers a current benchmark for obstetricians’ practices regarding assessment and 
administration of vaccines to pregnant women. The last national surveys on this topic were 
performed in 200740 and 2009,41 although the latter had a very low response rate. In the 
2007 study, Power et al reported that 79% stock and administer at least some vaccines, and 
among those, 61% of providers stocked and administered influenza vaccine to pregnant 
women, which translates to about 48% of obstetricians administering influenza vaccine to 
pregnant women. The 2009 study, performed during the H1N1 pandemic season, reported 
71% administered influenza vaccine, although that survey was more prone to response bias 
given a response rate of 15%. This study suggests that there has been substantial progress, 
with 85% of ob-gyns who care for pregnant women now administering influenza vaccine to 
their pregnant patients. Stocking the vaccine matters, as previous work has shown that 
women who received both a recommendation and an offer of vaccination were about twice 
as likely to receive influenza vaccine as those who received a recommendation alone.28 It is 
noteworthy that while approximately half of providers in 2007 stocked and administered 
influenza vaccine to pregnant women, vaccination coverage for influenza vaccine in the 
2007–2008 season among pregnant women was only 27%42 compared to 50% in the 2014–
2015 season. There is no evidence that pregnant women’s attitudes regarding acceptance of 
influenza vaccination have improved in the intervening years, and some evidence that safety 
concerns have actually increased.43 It may be that the important increases in uptake of 
influenza vaccination among pregnant women can primarily be attributed to improved 
vaccine delivery by obstetricians.
Barriers to stocking and administering vaccines to pregnant women by obstetricians continue 
to be primarily financial, particularly for inadequate reimbursement for vaccine purchase 
and vaccine administration. Although the questions were asked differently, these findings are 
similar to the findings of Power et al from 2007, where roughly half of physicians endorsed 
statements regarding financial barriers. These findings are discouraging given the extensive 
efforts to increase access to adult vaccination among vaccine advocates and the stipulations 
of the Affordable Care Act that all Advisory Committee on Immunization Practices (ACIP) 
recommended vaccines be covered by non-grandfathered insurance companies with no 
copay (first dollar coverage). In contrast to the Powers study, though, attitudinal barriers 
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among obstetricians themselves have essentially disappeared. The most direct comparison 
between the two studies is regarding safety: in 2007, 32% of respondents agreed that “we 
still don’t know enough about the effects of vaccines on the fetus to administer them safely 
in pregnancy.” In this study, obstetricians’ concern about the safety of vaccines in pregnancy 
was reported as ‘not a barrier’ by 88% of respondents. On the other hand, patient attitudinal 
concerns regarding vaccination in pregnancy was a significant perceived barrier for many 
ob-gyns, suggesting the need for ongoing efforts to improve pregnant women’s acceptance 
of vaccination.
The findings of the multivariable analysis offer some insight into reasons some physicians 
are not following the recommendation to administer influenza and Tdap vaccines to 
pregnant women, and may provide a better understanding of some of the barriers. The 
finding that more women than men administer these vaccines is consistent with prior 
literature showing that female physicians are more likely to adhere to clinical 
guidelines44–46 and provide preventive care more often.47–54 The finding that those 
administering both vaccines perceive more patient barriers may be related to the fact that 
because they are administering both vaccines, they are experiencing more patient resistance 
than those physicians who do not. Physicians who are in private practice were also less 
likely to administer these vaccines. This may be because hospitals and larger systems are 
better equipped to overcome the financial and logistical barriers to vaccine delivery. Such 
organizations likely already stock these vaccines for use in other settings, and they also often 
have the infrastructure necessary to implement system-level changes that strongly promote 
guideline adherence. One explanation for why physicians who do not stock both vaccines 
report greater financial barriers is because these may be perceived barriers more than they 
are true barriers. Ob-gyns who stock and administer these vaccines report fewer financial 
barriers; this fact should offer some encouragement to those currently not stocking these 
vaccines. Providers may also benefit from increased use of available resources. For example, 
more than half of ob-gyns rarely or never use the ACOG immunization toolkits. These 
toolkits have extensive information on vaccine financing and coding that could address some 
of the perceived financial barriers.55
Ob-gyns reported infrequent use of several evidence-based strategies for increasing 
vaccination uptake. While a sizable proportion reported use of standing orders, more for 
influenza vaccine than for Tdap, few reported using reminder/recall or an IIS. An IIS is a 
confidential, population-based, computerized database that records all immunization doses 
administered by participating providers to persons residing within a given geopolitical area.
56,57
 Infrequent use of IISs by ob-gyns is not surprising given the infrequent use by other 
specialties delivering primary care primarily to adult patients, such as internists,58 and the 
lack of infrastructure for supporting adult vaccination recording in IISs in many states.57 
More frequent use of IIS by ob-gyns is a worthy goal, but there are many systemic barriers 
that will need to be resolved prior to widespread adoption. It may also be that for the routine 
vaccines of pregnancy, influenza and Tdap, ob-gyns do not perceive a need to use an IIS. 
Similarly, reminder/recall for these routine vaccines may be perceived as unnecessary since 
patients are seen so frequently during a pregnancy. However, for other vaccines indicated for 
some pregnant women, systematic reminder/recall may be a well-suited strategy as it could 
take the need for determining eligibility for infrequently delivered vaccines out of the busy 
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provider’s hands. Because there does not appear to be a common systematic way for 
determining eligibility for these other vaccines, though, frequent use of reminder/recall by 
ob-gyns – similar to adoption of IIS – is unlikely to happen anytime soon.
This study has several strengths and limitations. It was from a nationally representative 
sample of ob-gyns, and there was a high response rate. However, respondents’ attitudes and 
practices may have differed from non-respondents, and network physicians may differ from 
physicians overall, although prior work suggests not.34 Also, this survey assessed practices 
of only ob-gyns, so other prenatal care providers such as family physicians and nurse 
midwives are not represented. Future work should examine maternal vaccination practices 
among these providers, as their professional organizations strongly endorse vaccination of 
pregnant women, yet there have been no recent national surveys assessing their practices and 
attitudes. Finally, this study assessed reported practices; actual practices were not observed.
Ob-gyns have made great strides in the delivery of influenza and Tdap vaccines in pregnancy 
in recent years. However, significant gaps remain: A quarter of ob-gyns are still not stocking 
Tdap vaccine leaving many infants vulnerable to pertussis, and for vaccines other than 
influenza and Tdap that may be indicated in pregnancy, most ob-gyns are not assessing 
eligibility and even fewer are stocking these vaccines. To address these gaps, novel 
approaches may be needed, such as a program for pregnant women similar to the Vaccines 
for Children (VFC) program, which has been instrumental in increasing uptake of childhood 
vaccines. Future work should address the feasibility of more complete vaccine delivery in 
ob-gyn settings, exploring and addressing potential barriers, and offering sustainable 
solutions.
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Figure 1. Assessment of Vaccination Status and Vaccines Administered to Pregnant Patients by 
US Obstetrician-Gynecologists, 2015 (n=324)
Tdap, tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine; MMR, 
measles, mumps and rubella vaccine; HPV, human papillomavirus vaccine; Td=tetanus and 
diphtheria toxoid vaccine; assessment for pneumococcal vaccination status was generic and 
not specific to either vaccine.
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Figure 2. Barriers to Stocking and Administering Vaccines among US Obstetrician-
Gynecologists, 2015 (n=324)
Some percentages do not add up to 100% due to rounding
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Table 1
Respondent and Non-Respondent and Other Practice Characteristics of US Obstetrician-Gynecologists 
Surveyed, 2015 (n=482)
Characteristic OB-GYN
Respondents (n=353) Non-Respondents (n=129) P-Valuea
Age in years, mean (SD) 48.9 (10.8) 49.2 (10.6) 0.86
Male, % 29.9 42.2 0.01
Region, %
 Midwest
21.3 18.6
 Northeast 19.8 26.4
 South 36.0 36.4
 West 23.0 18.6 0.39
Location of Practice, %
 Urban
55.5 57.4
 Suburban 41.6 41.1
 Rural 2.8 1.6 0.71
Setting, %
 Private practice
64.9 76.6
 Hospital/clinic 27.3 15.6
 HMO 7.8 7.8 0.03
Number of Sites in Multi-site System, %
 2–3
17.6 NA
 4–6 22.9 NA
 7–9 15.4 NA
 ≥10 44.1 NA NA
aWilcoxon test
Abbreviations: OB-GYN, obstetrician-gynecologist; HMO, health maintenance organization.
Note: Boldface indicates statistical significance (p<0.05)
Am J Prev Med. Author manuscript; available in PMC 2019 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
O’Leary et al. Page 15
Table 2
Factors Associated with Giving Both Tdap and Influenza Vaccines Among US Obstetricians-Gynecologists, 
2015 (n+294)a
Variable Does not give both 
Tdap and 
influenza vaccines
n=78 (27%)
%
Gives both Tdap 
and influenza 
vaccines
n=216 (73%)
%
Bivariate PR (95% CI) Multivariable PR 
(95% CI)
Gender**
 Male 49 25 0.73 (0.60–0.88) 0.78 (0.66–0.93)
 Female 51 75 Ref. Ref.
Mean (sd) age in years 52.7 (11.0) 46.7 (10.6) 0.93 (0.90–0.96) per 5 
years
Setting**
 Private practice 86 54 Ref. Ref.
 Other (Hospital/clinic, HMO, Public 
Health, University)
14 46 1.43 (1.25–1.62) 1.23 (1.08–1.39)
Region
 Midwest 15 24 1.28 (1.06–1.54)
 Northeast 19 18 1.14 (0.91–1.42)
 South 49 31 Ref.
 West 17 28 1.30 (1.08–1.55)
Mean (sd) Factor 1* Financial Barriers 
(per 1 point)b
1.9 (0.8) 1.1 (0.8) 0.82 (0.77–0.88) 0.86 (0.77–0.96)
Mean (sd) Factor 2** Patient 
Attitudinal Barriers (per 1 point)
1.2 (0.7) 1.4 (0.7) 1.11 (1.03–1.21) 1.16 (1.07–1.26)
Mean (sd) Factor 3* Practice Barriers 
(per 1 point)
1.7 (0.9) 1.0 (0.8) 0.82 (0.76–0.88) 0.87 (0.78–0.97)
Mean (sd) Factor 4 Visit-level Barriers 
(per 1 point)
1.3 (0.8) 1.3 (0.7) 0.99 (0.90–1.08)
Abbreviations: Tdap, tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine; PR, prevalence ratio; CI, confidence interval; ref., 
reference; sd, standard deviation; HMO, health maintenance organization.
a
n of 294 includes physicians providing care to pregnant patients with non-missing outcomes
bCronbach’s alpha for factors: 1=0.89; 2=0.87; 3=0.80; 4=0.68
Note: Boldface indicates statistical significance (*p<0.05, **p<0.01)
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